Alexander disease (AxD) is a leukodystrophy caused by heterozygous mutations in the gene for glial fibrillary acidic protein, an intermediate filament protein expressed by astrocytes. The mutation causes prominent protein aggregates inside astrocytes; there is also loss of myelin and oligodendrocytes and neuronal degeneration. We show that immunohistochemical staining for glutamate transporter 1, the major brain glutamate transporter expressed primarily in astrocytes suggests decreased levels in the hippocampi of infantile AxD patients. A knock-in mouse model of AxD also shows significant reduction of glutamate transporter 1 in the hippocampus. To explore this phenomenon at the cellular level, wild-type and R239C mutant glial fibrillary acidic proteins (the most common mutation) were overexpressed in astrocytes in culture. Western blotting and whole-cell patch clamp recordings demonstrated that the R239C astrocytes exhibited markedly reduced glutamate transporter 1 protein levels; this resulted in attenuated or abolished glutamate-induced inward transporter current. Neurons cocultured with the R239C astrocytes exhibited increased death after glutamate challenge. These results indicate that aberrant astrocytes have decreased glutamate uptake, which may play an important role in the pathogenesis of neuronal and oligodendrocyte injury and death in AxD.
INTRODUCTION
Alexander disease (AxD) is a degenerative neurological disorder mainly of infants and children that causes progressive macrocephaly, psychomotor regression, intractable seizures, and eventual death. Pathological changes in the central nervous system (CNS) include loss of oligodendrocytes and myelin in white matter and variable loss of neurons, most commonly in the hippocampus, striatum, and neocortex (1Y4). The pathological hallmark of AxD is the Rosenthal fiber (RF), a proteinaceous inclusion in astrocytes. Among the known components of RFs are the intermediate filament protein glial fibrillary acidic protein (GFAP), small heat-shock proteins including >B-crystallin and hsp27, and plectin, a filamentbinding protein (5Y7). Heterozygous point mutations in the GFAP gene, which is expressed almost exclusively in astrocytes, have been identified in most AxD patients (8) . The fact that GFAP is not expressed in neurons or oligodendrocytes implies that the cellular degeneration in the AxD brain is secondary to disrupted or pathological interactions between astrocytes and other cell populations.
One of the most pivotal findings for our understanding of neuron-glia communication was the discovery of a family of high-affinity Na + -dependent glutamate transporters (GluTs) in the CNS (9Y14). Although both neurons and astrocytes express GluTs, glutamate entry into astrocytes via astrocytic GluT is the predominant route for removal of glutamate from the synaptic cleft between neurons (15Y17). In vivo and in vitro studies have provided compelling evidence that glutamate uptake by astrocytes effectively maintains low extracellular glutamate concentrations, thus affording protection to neurons from excitotoxicity. There are 2 main subtypes of GluTs in astrocytes of the mammalian forebrain and cerebellum: glutamate-aspartate transporter (GLAST, EAAT1) and GluT-1 (GLT-1, EAAT2) (18) . Both can transit between the intracellular compartment and the membrane surface. Glutamate transporter activity is frequently related to the relative amount of GluT that translocates to the cell surface (19) . Malfunctions of GluTs have been implicated in the pathogenesis of several neurological disorders such as epilepsy, amyotrophic lateral sclerosis, Alzheimer disease, Huntington disease, hypoxia/ischemia, stroke, and head trauma (20, 21) .
In this study, we investigated GluT levels in AxD. We reasoned that alterations could underlie abnormal glialneuronal communication in this disease. Alexander disease brain sections and hippocampal tissues of knock-in mice heterozygous for a mutant GFAP have markedly reduced GLT-1 levels. Although the AxD patients had seizures, the mouse model shows reduced GLT-1 levels in the absence of seizures, underscoring the fact that the decrease in GLT-1 is not simply a consequence of seizure activity. At the cellular level, we examined functions of astrocytes that overexpress mutant GFAP and found marked downregulation of GLT-1 transcripts and
MATERIALS AND METHODS

Reagents and Antibodies
DNA cloning enzymes were purchased from New England Biolabs (Beverly, MA). Cell culture medium and supplements were from Sigma (St Louis, MO). We used antibodies against Type III A-tubulin (1:2000; TuJ1, MMS435P; CRP Inc), NeuN (1:100; MAB733, Chemicon, Temecula, CA), microtubule-associated protein 2 (1:1000; MAP-2, ab77 56; Abcam, Cambridge, MA), Olig-2 (1:100; kindly provided by Dr Tom Jessell, Columbia University), paired box gene 6 (2 Kg/mL; Pax6, AB5409; Chemicon), GFAP (1:1000; SMI22; Sternberger Monoclonals, Baltimore, MD), Vimentin (1:500; MAB3400; Chemicon), S100A (1:1000; Z0311; DAKO, Carpinteria, CA), GLAST (1:1000; AB1782, Chemicon), and GLT-1 (1:50; AB1783; Chemicon), myelin basic protein ([MBP] 1:1000; SMI-99; Sternberger Monoclonals, Inc), SV40 Large T Antigen (1:100; 554149; PharMingen, San Diego, CA), green fluorescent protein ([GFP] 1:500; A11122; Molecular Probes, Eugene, OR; 1:1000; MAB3580; Chemicon). Rabbit antiYGLT-1 (1:1000) and rabbit anti-GLAST (1:1000) antibodies for Western blotting were generous gifts from Dr Michael Robinson (University of Pennsylvania) and Dr Jeffrey Rothstein (Johns Hopkins University). All secondary antibodies were obtained from Southern Biotech.
Brain Tissue
All AxD cases were diagnosed based on histopathologic examination and confirmed by molecular genetic analysis for GFAP mutation. Immunostaining and Western blot analyses were carried out with fixed and frozen CNS tissues from AxD patients with R239C, R239H, and R416W mutations. All were children who manifested the disease as infants and died within the first decade (10 years, 29 months, and 7 years). All showed similar and typical pathology for AxD, with severe leukodystrophy and numerous RFs. All postmortem intervals were less than 10 hours. Controls included frozen CNS tissue from 2 children: one with no neurological disease, aged 20 months, 18-hour postmortem interval and the other with WerdnigHoffman disease (non-AxD, nonleukodystrophy neurological disease without RFs), aged 22 months, 6-hour postmortem interval. For immunohistochemistry, the tissue was fixed in formalin and then embedded in paraffin. We did not have access to fresh-frozen hippocampal or striatal tissues.
Western Blotting
Cells were washed with cold PBS and then lysed on ice for 10 minutes in radioimmunoprecipitation assay lysis buffer (Pierce, Rockford, IL). Lysates were sonicated for 20 seconds and centrifuged at 13,000 Â g for 15 minutes at 4-C. Aliquots of 20 Kg of protein were loaded on a 4% to 12% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis gel (NP0321box, Invitrogen, Carlsbad, CA) for electrophoresis and subsequently blotted to a nitrocellulose transfer membrane (Protran BA83; Whatman Inc, Piscataway, NJ). After blocking with 5% skim milk, membranes were incubated with primary antibodies and mouse antiYglyceraldehyde 3-phosphate dehydrogenase (ab9485; Abcam), followed by a reaction with secondary antibodies conjugated to peroxidase. Proteins reactive with the antibodies were visualized using the enhanced chemiluminescence system (Amersham Biosciences, Buckinghamshire, UK) on Kodak Biomax films (Kodak, Japan), with glyceraldehyde 3-phosphate dehydrogenase as internal control.
Immunofluorescence Microscopy and Hoechst Staining
Cells grown on coverslips were fixed for 5 minutes with 4% paraformaldehyde in PBS and then washed with 0.5% Triton X-100 in PBS for 10 minutes. Primary and secondary antibodies were diluted in PBS/0.1% Triton X-100/5% bovine serum albumin. Cells were incubated for 1 hour with primary antibodies and for 30 minutes with secondary antibodies at 37-C. For nuclear staining, cells were treated with 10 Kg/mL Hoechst 33258 (Sigma) in PBS for 15 minutes followed by incubating with primary and secondary antibodies and mounted in Gel/Mount medium (Biomeda, Foster City, CA).
RC2E10 Cell Cultures
RC2E10 cells were derived from primary embryonic cells (E16) of the rat cortex and immortalized by stable retroviral infection with the temperature-sensitive mutant of the SV40 T antigen and were a generous gift from Dr Mario Vallejo (Madrid, Spain) (22) . Cells were maintained and expanded at 33-C (permissive temperature) in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (D10) and then differentiated into astrocytes after raising the temperature to a nonpermissive level and adding 8-bromocAMP . Slight modifications to the original protocol were made for induced astrocyte differentiation. Cells were transferred to a 37-C incubator instead of a 39-C incubator and preincubated for 48 hours in D10 to inactivate the SV40 T antigen activity (confirmed by Western blotting, data not shown) and another 48 hours during which cells stopped proliferating. Subsequently, D10 was replaced by serum-free Dulbecco modified Eagle medium containing N1 supplement and 1 mmol/L sodium pyruvate with 20 ng/mL basic fibroblast growth factor (Defined Medium [DM]) for 24 hours. Differentiation was initiated by adding 8-BrcAMP (1 mmol/L) to DM. Most cells (85.3% T 11%) became GFAP positive and exhibited a process-bearing morphology after 4 days of 8-BrcAMP induction. Glial fibrillary acidic protein expression and astrocyte-looking morphology persisted for up to 26 days with no apparent cell loss as long as the cells were maintained under these culture conditions, even after the removal of 8-BrcAMP after 4 days (DM without 8-BrcAMP and other supplements).
Expression Constructs
RC2E10 cells were maintained at 33-C and infected with retroviral construct pQCXIX-IRES-eGFP (modified from Clontech's pQCXIX) containing cDNA encoding wild-type (WT) or arg239cys (R239C) GFAP inserted between the BamHI and EcoRI sites. Retroviral expression vectors (WT-GFAP-IRES-eGFP and RC-GFAP-IRES-eGFP) were generated and propagated in gp293 cells with the help of vesicular stomatitis virus G protein, as described (23) .
Flow Cytometry
Forty-eight hours after retroviral infection of RC2E10 cells at the permissive temperature of 33-C, cells were trypsinized and resuspended in 20% fetal bovine serum in 1Â PBS and sorted into DM using a BC FACSAria flow cytometer (BD Biosciences, San Jose, CA). Cells were gated on Forward and Side Scatter, Singlets, and Viable cells using 0.5 Kg/mL 4 ¶,6-diamidino-2-phenylindole (Invitrogen). Cells were excited with a 488-nm laser, and fluorescence emission of 530 nm was collected to select the GFP-positive cells. Cells were collected into a chilled 5-mL conical tube containing PBS/5% normal goat serum. Purity was greater than 98% as analyzed by microscopy using anti-GFP antibodies.
Electrophysiology
Astrocytes were plated on polylysine-coated glass coverslips at 3 Â 10 6 cells/coverslip in DM 3 to 4 days after 8-BrcAMP differentiation and subjected to whole-cell patch clamp recording. Cells were transferred into a bath chamber with oxygenated-modified artificial cerebrospinal fluid (in mmol/L): 125 NaCl, 2.5 KCl, 2 CaCl 2 , 1.5 MgCl 2 , 1.25 NaH 2 PO 4 , 26 NaHCO 3 , and 10 dextrose. The chamber was perfused at a flow rate of 1.5 mL/min and a temperature of 32-C. Patch pipettes were filled with a solution containing (in mmol/L) 140 KCl, 1 MgCl 2 , 10 EGTA, 10 HEPES, 3 MgATP, and 0.3 Na 2 ATP, pH 7.3, with KOH. Pipette resistance ranged from 3 to 6 M6 when filled with internal solution. Cells were voltage clamped at a holding potential of 70 mV using the MultiClamp 700A patch-clamp amplifier with software MCC 700A Version 1.1.2.27 and pClamp 8 (Axon Instrument, Foster City, CA). Cell capacitance and series resistance was monitored throughout the experiments, and cells were discarded if the series resistance changed by more than 10%. Values of the resting membrane potentials were obtained at the start of the experiment and corrected for the pipette tip potential. The input resistance and membrane conductance were measured at a membrane potential of 70 mV, using a membrane test program in pClamp 8. L-glutamate (1 mmol/L) was applied by using a focal pressure perfusion system (Pressure System, Toohey Company; Fairfield, NJ). The tip of the electrode that was used for puffing glutamate was approximately 2 mm in diameter. Other drugs for whole-cell patch recordings were applied to the bath at final concentrations of dihydrokainic acid (300 Kmol/L), 6-nitro-7-sulfamoylbenzo [f]quinoxaline-2,3-dione (50 Kmol/L), (S)->-methyl-4-carboxy-phenyl-glycine (500 KM), 10 (RS)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid were purchased from Tocris (Ellisville, MO). Threo-A-hydroxyaspartate (250 Kmol/L) and L-glutamate (1 mmol/L) were purchased from Sigma.
Hippocampal Cultures
Rat hippocampal neurons (Sprague Dawley, P1) were prepared as previously described (24) . In brief, cells were seeded on polylysine-coated glass coverslips (6 Â 10 4 cells/ coverslip) seated at the bottom of a 24-well tissue culture plate (Falcon, San Jose, CA) and maintained in Neurobasal media with B27 supplement (Gibco-BRL, Carlsbad, CA) at 37-C. Proliferation of non-neuronal cells was inhibited by adding 5-fluorouracil (20 Kmol/L) at 20 to 40 hours after plating for 72 hours, and medium was exchanged every 2 days. Cells were used at 10 days in vitro.
Noncontact Transwell Cocultures
We followed a neuron/astrocyte coculture protocol described in detail (25) . Astrocytes were trypsinized and transferred into a transwell insert (0.40 Km pores, 5 Â 10 4 cells/ insert membrane) sitting 1 mm above the bottom layer of neurons growing in the 24-well tissue culture plate. Thus, the neurons and astrocytes are cultured in the same medium (Neurobasal + B27) for 24 hours but are not in direct contact. For the induction of neuronal death, cocultures were exposed to 1 mmol/L glutamate for 30 minutes in a solution containing (in mmol/L) 20 HEPES, 120 NaCl, 5.4 KCl, 0.8 MgCl 2 , 1.8 CaCl 2 , and 15 glucose, pH 7.4. After 3 extensive washes with control solution, cocultures were maintained for another 17 hours before staining with anti-MAP2 and Hoechst 33258. Stained neurons and their nuclei were counted in 10 randomly selected fields of a 20Â microscope objective per well. Control cultures were grown as previously described but not exposed to glutamate. The GFP-positive astrocytes were counted again at this time to ensure comparable numbers of WT and R239C astrocytes in cultures.
RT-PCR From Mouse Hippocampi
Hippocampi from 3 GFAP +/+ and 4 GFAP + /R236H mice at 3 months of age were homogenized separately in 500 KL Trizol and RNA extracted according to the manufacturer's protocol (Invitrogen) (26) . cDNA were synthesized from 1 mg of total RNA by reverse transcription with Superscript II (Invitrogen) in a 20-mL reaction, as previously described (27) . Primers specific for the GLT1 gene (Slc1a2 forward: 5 ¶-GCC TGG ATC ACT GCT CTG GGA ACT-3 ¶; reverse: 5 ¶-CCG ACT GGG AGG ACG AAT CTG GT-3 ¶, accession NM_011393) were used with SYBR Green polymerase chain reaction (PCR) Master Mix in an Applied Biosystems 7500 real-time PCR System (Foster City, CA) to quantify GLT-1 transcript relative to 18S ribosomal RNA. Mice used for the RT-PCR and the protein lysates were in the 129S6 genetic background.
RESULTS
Loss of Neurons Correlates With Severe Gliosis and Loss of GLT-1 Immunoreactivity in the AxD Hippocampus
We examined hippocampi from 3 infantile AxD patients ( + /R416W; + /R239C; and + /R239H), all of whom had experienced generalized seizures. In the AxD hippocampus ( + /R416W), GLT-1 immunoreactivity was substantially lower in the CA1 region than in CA2 (Fig. 1B , and at higher magnification in Figs. 1E, F) . This decrease correlated with an almost complete loss of neurons in CA1 but with preservation of neurons in CA2 (Figs. 1A, C, D) . The loss of neurons and GLT-1 immunoreactivity in CA1 were also found in the other AxD patients. Despite the apparent decrease of GLT-1, CA1 is well populated by astrocytes, detected by S100A immunostaining (Fig. 1G ) and GFAP immunostaining (not shown). Thus, the loss of GLT-1 does not reflect a loss of astrocytes. Similar observations were also made in the hippocampi of 2 additional AxD patients (data not shown). The GLT-1 immunostaining of control hippocampi showed similar signal levels in all pyramidal cell sectors, with no apparent decreased signal in CA1 (Figs. 1I, J) . The antiYGLT-1 antibody reacts specifically with astrocytes, as shown by confocal imaging in a normal hippocampus (Fig. 1H) .
GFAP-R236H Mice Exhibit a Diminished Level of GLT-1 in the Hippocampus
Because children with AxD invariably experience seizures, it was difficult to determine whether the lower GLT-1 immunostaining was a result of the gliosis secondary to the seizures or was intrinsic to AxD, or both. Therefore, we examined the hippocampi of mice heterozygous for the R236H GFAP mutation (R236H/ + , and corresponding to the R239H mutation in human AxD). These mice develop normally and survive without gross dysfunction, but they display an increased susceptibility to kainate-evoked seizures and evidence for widespread oxidative stress (26) . Most importantly, the kainate-evoked seizures cause massive neuronal death in the CA1 region of the hippocampus in R236H/ + mice, but not in WT mice (26) . To examine GLT-1 expression in these mice, we examined hippocampal sections from 2-month-old mice that had not undergone induced seizures. Sections double stained with anti-GFAP and GLT-1 (Fig. 2A ) demonstrated markedly stronger GFAP staining and enlarged astrocytes with thickened processes in the R236H/ + mice compared with their normal appearance in WT mice. In addition, tissue from the R236H/ + mice displayed weaker staining with the GLT-1 antibody than that in WT controls (Figs. 2A, panels b, d , f, and h). No appreciable loss of hippocampal neurons was observed in either R236H/ + or WT mice without seizures (26) . A Western blot of hippocampal extracts from 3 R236H/ + and 3 WT littermate mice confirmed that GLT-1 protein levels were significantly decreased (Fig. 2B, GLT-1 ) and that GLAST levels were also modestly reduced (Fig. 2B, GLAST) in the R236H/ + hippocampi. Notably, the R236H/ + mice exhibited a marked increase in GFAP levels compared with controls (Fig. 2B) . We also performed RT-PCR on hippocampal RNA extracts from 3-month-old mice and found a 36% decrease in GLT-1 mRNA in the R236H/ + mice relative to WT mice (Fig. 2C) . Thus, in the absence of seizures, the levels of GLT-1 mRNA and protein are significantly lower in the heterozygotes.
Creation of Astrocyte Cell Lines Stably Expressing WT and R239C GFAP
A body of evidence supports the idea that achieving persistently high levels of GFAP protein is critical to mimic the pathology of AxD (26Y30). Astrocytes cultured from neonatal R236H knock-in mice, however, show relatively few GFAP inclusions (Woosung Cho, personal communication). As an alternative, we took advantage of an established model of astrocytes (22) and genetically manipulated them to generate a large mass of astrocytes possessing mutant GFAP aggregates. RC2E10 cells derived from primary embryonic cells (E16) of the rat cortex and immortalized by stable infection with the temperature-sensitive mutant of the SV40 T antigen (22) , cycle at 33-C, and then differentiate into astrocytes at a nonpermissive temperature in the presence of 8-BrcAMP. At 37-C, 85.3% T 11% of the cells became GFAP positive and coexpressed S100A, GLT-1, and GLAST, but not EAAC1 (Fig. 3a) , MAP2, NeuN, Tuj1, Pax6, Olig2, or MBP (data not shown).
The application of glutamate to astrocytes evokes an inward current (iGlu) caused by activation of GluTs and translocation of a net positive charge, including 3 Na + ions with glutamate (31Y33). We recorded iGlu mediated by glutamate uptake using voltage-clamping in RC2E10-derived astrocytes (Fig. 3b) . The iGlu was completely blocked by threo-Ahydroxyaspartate (250 Kmol/L), a potent general inhibitor of GluTs but not by a cocktail of glutamate receptor (GluR) antagonists, indicating a dominant contribution of GluTs to the iGlu (Fig. 3b) . Therefore, iGlu is a valid surrogate measure of glutamate uptake in these cells (31Y33).
To model pathological inclusions in astrocytes of AxD and directly explore the cellular consequences of expressing the R239C mutation, we generated 3 astrocyte cell lines by retroviral-mediated gene transfer. RC2E10 cells were infected at 33-C with a control retroviral vector (VEC, expressing eGFP but not GFAP) or with vectors carrying WT or R239C GFAP. To examine the capacity of the GFAP to aggregate, we wanted to express WT and R239C GFAP at equivalent levels. This was done by FACS selection of cells expressing similar levels of GFP, a reporter gene in our retroviral construct stably integrated into the astrocyte genome (retro-GFAP-IRES-GFP). Glial fibrillary acidic protein and GFP expression levels from this construct are directly proportional; cells expressing high levels of GFP contain high levels of GFAP, and vice versa (data not shown). By counting GFP-positive cells with inclusions at 37-C after 8-BrcAMPYmediated differentiation, we found that with increasing levels of GFAP, R239C GFAP FIGURE 2. Reduced levels of glutamate transporter 1 (GLT-1) in the hippocampus of glial fibrillary acidic protein (GFAP)-R236H heterozygous mice. (A) Indirect immunofluorescence detection of GFAP (green), GLT-1 (red) in hippocampi of wild-type (WT), and GFAP-R236H knock-in (R236H) mice at 8.5 weeks. The hippocampus of R236H mice (b, d) shows increased GFAP immunoreactivity and loss of GLT-1 compared with WT mice (a, c). Panels (c) and (d) are the same images as (a) and (b), but without the GFAP signal. CA1 sector of the hippocampus is shown magnified in (e), (g), (f), and (h). Panels (g) and (h) are the same images as (e) and (f) without the GFAP signal. Each set of images was taken exactly at the same exposure settings. Scale bars = (aYd) 500 Km; (eYh) 100 Km. aggregates more rapidly than WT GFAP; the latter displayed a typical filamentous network throughout the cytosol. The increased propensity for R239C GFAP to form inclusions was also observed in previous studies using transient expression assays (5, 34) . Most R239C astrocytes exhibited irregularly shaped processes and aggregates of filaments, whereas VEC and WT astrocytes formed well-organized GFAP filament bundles (Fig. 3c) . Using patch clamping, we found that the VEC and WT astrocytes showed passive membrane current and a linear current-voltage (I-V) curve (Figs. 3d, e) , similar to the RC2E10 astrocytes that had not been retrovirally infected (data not shown). R239C astrocytes also showed a linear I-V relationship, but the membrane resistance was significantly higher than that of astrocytes expressing WT GFAP (R239C, 556.1 T 5.2 M6, n = 20; WT, 25.2 T 7.4M6, n = 28, p G 0.01) (Fig. 3e) . This difference may be attributed to a marked loss of gap junction connectivity, as revealed by microinjection of Lucifer yellow (WT, 4 T 1 coupled cells per injection, n = 28; R239C, no coupled cells per injection, n = 20). We do not know yet whether the R239C GFAP alters expression of gap junction proteins.
R239C Astrocytes Exhibit Reduced GLT-1 Levels and Impaired GluT Activity
Significant differences in the protein profiles of the control and R239C astrocyte cell lines were readily detected by Western blotting 24 hours after 8-BrcAMPYinduced differentiation. Glutamate transporter 1 protein level was significantly decreased in R239C astrocytes relative to control and WT cells (Fig. 4a) . As expected, the amount of GFAP protein produced endogenously by VEC astrocytes was much lower than in WT and R239C astrocytes. All of these protein patterns remained similar from Day 9 to Day 14 in the absence of 8-BrcAMP (data not shown), suggesting that the changes of GLT-1 cannot simply be attributed to the effects of 8-BrcAMP.
To test whether reduced levels of GLT-1 in R239C astrocytes are associated with a decrease in GluT activity, we measured iGlu under voltage clamp conditions (Vm, j70 mV; Fig. 4b ). In these experiments, cultures were exposed to a mixture of GluR antagonists (50 Kmol/L 6-nitro-7-sulfamoylbenzo [f]quinoxaline-2,3-dione, 500 Kmol/L (S)->-methyl-4-carboxy-phenyl-glycine, 40 Kmol/L 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) to block any currents caused by GluR activation. Under these conditions, the inward current evoked by glutamate was nearly completely abolished by 250 Kmol/L THA, a general GluT blocker. Strikingly, a 77.2% T 3.5% reduction in the magnitude of iGlu was observed in 20% of the R239C astrocytes, and no iGlu was observed in the rest of the R239C cells examined. The response patterns of iGlu in all 3 astrocyte lines are summarized in Figure 4c .
R239C Astrocytes Fail to Protect Hippocampal Neurons From Glutamate Toxicity in Cocultures
Integrating the previously mentioned findings in the context of AxD, we decided to assay directly for a cross-talk between astrocytes and hippocampal neurons in a transwell coculture system. We isolated embryonic mouse hippocampal neurons and cultured them for 10 days. Exposure to 1 mmol/L glutamate for 30 minutes followed by 17 hours without glutamate resulted in a substantial amount of neuronal death in the absence of astrocytes (35.2% T 10% survival with glutamate vs 91.6% T 8% survival without glutamate). We then examined glutamate-induced neuronal death in the presence of astrocytes expressing WT or R239C GFAP or astrocytes expressing the control retrovirus (VEC) (Fig. 5 ). Neurons cocultured with R239C astrocytes showed a marked amount of cell death when exposed to 1 mmol/L glutamate for 30 minutes followed by 17 hours without glutamate (14.7% T 14% survival). In contrast, the neurons survived far better when cocultured with WT GFAP (48.3% T 13% survival) or control astrocytes (61.9% T 11% survival). Data are means T SD of triplicate determinations; p G 0.01 for survival of neurons + R239C GFAP astrocytes compared with neurons + VEC or WT GFAP astrocytes. As a further control, incubating neurons with each of the 3 types of astrocytes in the absence of glutamate did not result in significant neuronal death.
DISCUSSION
Intractable seizures are a common clinical feature of AxD. Defective glutamate clearance by the GluTs on astrocytes would be compatible with a rise in extracellular glutamate and excessive excitatory activity of neurons, a concept that has been convincingly demonstrated by the high seizure susceptibility of GluT-deficient mice (15, 16) . Thus, we initially looked for alterations of GluTs in brain sections of AxD patients. A loss of GLT-1 immunoreactivity occurred in subcortical regions showing pronounced neuronal loss with no appreciable loss of astrocytes, that is, the hippocampus and striatum (latter not shown). In addition, the R236H knock-in mouse model of AxD (26) and the transgenic carrying multiple copies of the human R239H GFAP mutation (30) are hypersensitive to seizures induced by the glutamate receptor agonist, kainate. We found a depletion of GLT-1 protein in the R236H hippocampus. Note that under normal conditions, the mice do not show hippocampal neuronal loss, but after seizures, they experience extensive neuronal death in CA1, and that WT mice do not display neuronal death after seizures produced by the same dose of kainate (26) . Thus, although the lowered levels of GLT-1 in the R236H knock-in are not sufficient to cause neuronal loss under normal conditions, the CA1 pyramidal neurons are more susceptible to death under pathological conditions. We were not able to examine hippocampi of patients with AxD in the absence of seizures, however, because virtually all of them experienced seizures at some time.
Regulation of GLT-1 by GFAP Accumulation
How does accumulation of mutant GFAP regulate GLT-1 levels? One clue to a link is that astrocytes may selectively increase GLT-1 expression and GLT-1Ymediated glutamate transport via Akt activation (35) . We have found that the R239C astrocytes contained significantly lower levels of pAkt than the control astrocytes or the astrocytes that expressed WT GFAP (Tian et al, unpublished data). Akt activation is a complex process consisting of at least 2 sequential steps, membrane translocation and the subsequent phosphorylation of Akt at Ser473 and Thr308 (36, 37) . Therefore, the activation of Akt could be disturbed at either step. Akt translocates from the cytosol to the plasma membrane often near or at cell-cell or cell-matrix contacts. A simple yet logical explanation to the Akt inactivation is that R239C aggregates might sequester the cytosolic Akt away from its normal site of action (38) . In addition, accumulating evidence that disruption of gap junctional communication results in reduced PI3K/Akt activation (39Y41). In favor of such a possibility, we found that R239C astrocytes are poorly coupled, but additional experiments are needed to address the molecular links between GFAP mutations and Akt inactivation.
Intercellular Miscommunication in AxD
This is the first attempt to examine the pathogenesis of AxD in terms of cell-to-cell interactions. Our results in the neuron-astrocyte coculture system suggest a connection between astrocyte dysfunction and neuronal demise in AxD. Neurons cocultured with each of the 3 types of astrocytes in the absence of glutamate survived normally, suggesting that the R239C astrocytes do not secrete toxic substances. In the presence of glutamate, however, there seemed to be more neuronal death with the R239C astrocytes than in the neurons cultured without astrocytes. It is possible that glutamate itself stimulates the release of toxic substances from the R239C astrocytes. In addition to RFs and selective neuronal loss, another pathological feature of AxD is marked loss of oligodendrocytes. Because excitotoxicity caused by sustained high levels of extracellular glutamate damages not only neurons, but also oligodendrocytes (42Y49), it is possible that reduced capacity of the astrocyte GluTs may also contribute to axonal dysfunction and/or death of oligodendrocytes in AxD. The transgenic and knock-in mouse models of AxD do not show evidence of demyelination, but there is oxidative stress in white matter (26) . The difference between humans and mice in this regard may have to do with differences in glutamate receptor subunits in white matter and the fact that mice downregulate the expression of glutamate receptors in the white matter in ischemic conditions (50). 
Biologic Role of GFAP in Reactive Gliosis
The intercellular and intracellular signaling pathways mediated by mutant GFAP accumulation presented here may also provide functional insights into reactive gliosis, that is, astrocytic hypertrophy and an elevated content of GFAP that occurs in a wide variety of CNS disorders (18, 51, 52) . Despite a wealth of data attempting to ascribe biologic functions to GFAP upregulation in reactive astrocytes, it is still not known whether and to what extent these alterations are adaptive/ protective or detrimental, or both. Observations in AxD provide mechanistic evidence that link the prolonged accumulation of GFAP with astrocyte dysfunction. First, high levels of GFAP expression result in more inclusions, regardless of genotype. Mice that express the highest levels of either WT or human GFAP formed numerous RFs and died earlier than mice that expressed lower GFAP levels, suggesting that the severity of astrocyte pathology correlates with the gene dosage and degree of GFAP overexpression (26, 27) . The overproduction and accumulation of GFAP in astrocytes in vitro produce a marked cellular Bstress[ response characterized by the activation of MLK-MAPK pathways and an accumulation of shsps (53) .
Second, GFAP accumulation also seems to be linked to decreased glutamate transport. As summarized in Figure 4C , iGlu can be observed in 80% of VEC cells that expressed physiological levels of endogenous GFAP, whereas only 40% of WT GFAP overexpressers has a similar response. The partial inhibition of glutamate transport in response to the accumulation of WT GFAP suggests that astrocytes containing GFAP above a threshold level will eventually lead to aberrant GluT function. Such pathological processes have been suspected to be, at least in part, related to seizure development in tuberous sclerosis complex and temporal lobe epilepsy and to neuronal loss in amyotrophic lateral sclerosis (32, 54Y56) . Because reactive gliosis is associated with the accumulation of GFAP, our findings regarding the pathogenic events of AxD may be relevant to reactive gliosis in general. Indeed, it is possible that AxD is an extreme and exaggerated form of reactive gliosis. Thus, by identifying the impaired intracellular and intercellular signaling underlying this primary astrocyte disorder, we may also provide new windows into the nature and consequences of reactive gliosis.
